ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.

Background: Paclitaxel/carboplatin combination is the standard chemotherapeutic protocol for gynecologic cancers, but severe toxicities may compromise treatment. There is great inter-individual variability regarding the incidence and severity of toxicities, which may be due to single-nucleotide poly...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 76; no. 10; pp. 1401 - 1409
Autores principales: da Costa Junior, Luiz Carlos, de Castro, Clarissa Lourenço, Freitas-Alves, Daniely Regina, Vianna-Jorge, Rosane, Santos, Paulo Caleb Júnior Lima
Formato: research tables/charts Journal Article
Publicado: Springer Nature Oct2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145654892&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 145654892
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Oct2020
      vid: 76
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        145654892
        144438404
        145654892
        145654892
        10.1007/s00228-020-02934-9
        145654892
      ppf: 1401
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.
      aug:
        au:
          da Costa Junior, Luiz Carlos
          de Castro, Clarissa Lourenço
          Freitas-Alves, Daniely Regina
          Vianna-Jorge, Rosane
          Santos, Paulo Caleb Júnior Lima
        affil: Department of Pharmacology, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp), Rua Três de Maio, nº 100, 4° andar, Infar, Vila Clementino, 04044-020, São Paulo, SP, Brazil
      sug:
        subj:
          Genital Neoplasms, Female Drug Therapy
          Carboplatin Adverse Effects
          Paclitaxel Adverse Effects
          Polymorphism, Genetic
          Nephrotoxicity Risk Factors
          Hepatotoxicity Risk Factors
          Human
          Incidence
          Genotype
          Polymerase Chain Reaction Methods
          Odds Ratio
          Confidence Intervals
          Diabetic Patients
          Nausea Risk Factors
          Muscle Pain Risk Factors
      ab: Background: Paclitaxel/carboplatin combination is the standard chemotherapeutic protocol for gynecologic cancers, but severe toxicities may compromise treatment. There is great inter-individual variability regarding the incidence and severity of toxicities, which may be due to single-nucleotide polymorphisms (SNPs) affecting drug disposition or cellular sensitivity. Here we investigate the impact of selected SNPs in ERCC1, ABCB1, CYP2C8, and CYP3A5 genes on the incidence of severe toxicities, including nephro- and hepatotoxicity. Methods: A cohort of 507 gynecological cancer patients receiving paclitaxel/carboplatin was recruited at the Brazilian National Cancer Institute (INCA-Brazil). Clinical data were obtained during routine consultations or from electronic medical records. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0). Genotyping was performed using real-time PCR. Results: ABCB1 c.1236C>T was associated with moderate-to-severe (grades 2–4) nephrotoxicity (ORadjusted 2.40; 95% CI 1.39–4.15), even after adjustment for age (≥ 65) and diabetes. The risk association between ABCB1 c.1236C>T and moderate-to-severe nephrotoxicity following paclitaxel/carboplatin chemotherapy was also present among non-diabetic patients (ORadjusted 2.16; 95% CI 1.22–3.82). ERCC1 c.118C>T was the only individual variable associated with an increased risk for moderate-to-severe (grades 2–4) hepatotoxicity (OR 3.71; 95% CI 1.08–12.77), severe nausea (OR 4.18; 95% CI 1.59–10.95), and severe myalgia (OR 1.95; 95% CI 1.12–3.40). Conclusions: ABCB1 c.1236C>T and ERCC1 c.118C>T might serve as potential biomarkers for the risk of moderate-to-severe toxicities to carboplatin/paclitaxel chemotherapy of gynecological cancers.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N